(5-chloro-4-fluoro-2-methoxyphenyl)boronic acid | 949892-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (5-chloro-4-fluoro-2-methoxyphenyl)boronic acid
• CAS: 949892-09-5
• 化学式: C₇H₇BClFO₃
• 分子量: 204.393
• InChiKey: MROIVWKVBXFEMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.17
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-chloro-4-fluoro-2-methoxyphenyl)boronic acid 、 6-bromo-N-[(2,4-dimethoxyphenyl)methyl]-4-methylphthalazin-1-amine 在 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 1.0h， 以65.34%的产率得到6-(5-chloro-4-fluoro-2-methoxyphenyl)-N-[(2,4-dimethoxyphenyl)methyl]-4-methylphthalazin-1-amine
  参考文献：
  名称：

  [EN] INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF
  [FR] INHIBITEURS DE FACTEURS DU COMPLÉMENT ET LEURS UTILISATIONS

  摘要：

  揭示了式I和II的化合物及其药用盐。还披露了使用此处披露的化合物治疗神经退行性疾病、炎症性疾病、自身免疫疾病、眼科疾病或代谢性疾病的方法。

  公开号：

  WO2022020244A1
• 作为产物：
  描述：

  1-溴-5-氯-4-氟-2-甲氧基苯 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 0.67h， 以89%的产率得到(5-chloro-4-fluoro-2-methoxyphenyl)boronic acid
  参考文献：
  名称：

  NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY

  摘要：

  公开号：

  EP1995242B1

文献信息

• Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity
  申请人：Matsuda Mamoru

  公开号：US20090111807A1

  公开（公告）日：2009-04-30

  An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R 1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R 2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R 3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R 4 and R 5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R 6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R 7 represents OR 8 , NR 8 R 9 , SR 8 , S(O)R 8 , S(O) 2 R 8 ; and X represents O or S.

  本发明的目的是合成一种新的1,2,3,4-四氢喹喔啉衍生物，其化学式表示为（1），并找到该衍生物的药理作用。其中，R1代表卤素、烷基、环烷基、芳基或杂环基等；p表示0至5；R2代表卤素、烷基、羟基或烷氧基等；q表示0至2；R3代表氢、烷基、烯基、烷基羰基或芳基羰基等；R4和R5独立地表示氢、卤素、烷基、烯基、炔基、环烷基、芳基或杂环基等；R6代表氢、烷基、烯基、炔基、环烷基、芳基或杂环基等；A代表烷基；R7代表OR8、NR8R9、SR8、S（O）R8、S（O）2R8；X代表O或S。
• 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20130303537A1

  公开（公告）日：2013-11-14

  A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R 1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R 2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R 3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R 4 and R 5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R 6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R 7 represents OR 8 , NR 8 R 9 , SR 8 , S(O)R 8 , S(O) 2 R 8 ; R 8 and R 9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

  以下是由下式表示的1,2,3,4-四氢喹喔啉化合物：在式（1）中，R1表示卤素，烷基，环烷基，芳基或杂环基等取代基；p表示0至5；R2表示卤素，烷基，羟基或烷氧基等取代基；q表示0至2；R3表示氢，烷基，烯基，烷基羰基或芳基羰基等取代基；R4和R5独立地表示氢，卤素，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基；R6表示氢，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基；A表示烷基；R7表示OR8，NR8R9，SR8，S（O）R8，S（O）2R8；R8和R9独立地表示氢，烷基或烯基等取代基；X表示O或S。
• 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US08975256B2

  公开（公告）日：2015-03-10

  A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

  以下是由下式表示的1,2,3,4-四氢喹诺啉化合物：在式（1）中，R1代表卤素，烷基，环烷基，芳基或杂环基等取代基; p代表0到5; R2代表卤素，烷基，羟基或烷氧基等取代基; q代表0到2; R3代表氢，烷基，烯基，烷基羰基或芳基羰基等取代基; R4和R5独立地表示氢，卤素，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基; R6代表氢，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基; A代表烷基; R7代表OR8，NR8R9，SR8，S（O）R8，S（O）2R8; R8和R9独立地表示氢，烷基或烯基等取代基; X代表O或S。
• 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
  申请人：Matsuda Mamoru

  公开号：US08551991B2

  公开（公告）日：2013-10-08

  An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R4 and R5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; and X represents O or S.

  本发明的目的是合成一种新型的1,2,3,4-四氢喹喔啉衍生物，其化学式表示为(1)，并找到该衍生物的药理作用。其中，R1表示卤素、烷基、环烷基、芳基或杂环基等；p表示0到5；R2表示卤素、烷基、羟基或烷氧基等；q表示0到2；R3表示氢、烷基、烯基、烷基羰基或芳基羰基等；R4和R5分别表示氢、卤素、烷基、烯基、炔基、环烷基、芳基或杂环基等；R6表示氢、烷基、烯基、炔基、环烷基、芳基或杂环基等；A表示烷基；R7表示OR8、NR8R9、SR8、S(O)R8、S(O)2R8；X表示O或S。
• Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors
  申请人：AMGEN INC.

  公开号：US20160137636A1

  公开（公告）日：2016-05-19

  The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了I式化合物或其药学上可接受的盐，其为电压门控钠通道抑制剂，特别是Nav1.7。该化合物可用于治疗可通过钠通道抑制治疗的疾病，如疼痛障碍。还提供了含有本发明化合物的制药组合物。